Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020

Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020

Background: Monoclonal antibody (mAb) and Fc-fusion protein (FcP) are highly effective therapeutic biologics. We aimed to analyse consumption and expenditure trends in 14 Asia-Pacific countries/regions (APAC) and three benchmark countries (the UK, Canada, and the US). Methods: We analysed 440 mAb an...

Full description

Bibliographic Details
Main Authors: Cheng, F.W.T (Author), Hillen, J.B (Author), Lai, E.C.-C (Author), Lau, C.S (Author), Leung, W.K (Author), Li, X. (Author), Peng, K. (Author), Pratt, N.L (Author), Roughead, E.E (Author), Shin, J.-Y (Author), Stanford, T. (Author), Tong, X. (Author), Ward, M. (Author), Wong, I.C.K (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Accessibility
Affordability
Asia Pacific
Biological medicine
Fc-fusion protein
Healthcare professionals manpower
Healthcare systems
Monoclonal antibodies (mAb)
Unequal treatment access
Unmet needs
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items